CN1509288A - 5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐 - Google Patents

5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐 Download PDF

Info

Publication number: CN1509288A
Authority: CN; China
Prior art keywords: compound; citrate; ray diffraction; disease; diffraction pattern
Prior art date: 2001-05-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CNA028099117A

Other languages

English (en)

Chinese (zh)

Inventor

��ա�J��Լ��ѷ

菲利普·J·约翰逊

彼得R·罗斯

T

卢因·T·温特

R

格伦·R·威廉斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pfizer Products Inc

Original Assignee

Pfizer Products Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-14

Filing date

2002-04-26

Publication date

2004-06-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117854&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1509288(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-26 Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc

2004-06-30 Publication of CN1509288A publication Critical patent/CN1509288A/zh

Status Pending legal-status Critical Current

Links

Images

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Addiction (AREA)
Virology (AREA)
Diabetes (AREA)
Psychology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Endocrinology (AREA)
Oncology (AREA)
Obesity (AREA)
Hematology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Child & Adolescent Psychology (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Toxicology (AREA)

CNA028099117A 2001-05-14 2002-04-26 5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐 Pending CN1509288A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29086301P	2001-05-14	2001-05-14
US60/290,863		2001-05-14

Publications (1)

Publication Number	Publication Date
CN1509288A true CN1509288A (zh)	2004-06-30

Family

ID=23117854

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CNA028099117A Pending CN1509288A (zh)	2001-05-14	2002-04-26	5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐

Country Status (37)

Country	Link
US (1)	US6787549B2 (2)
EP (1)	EP1390366B1 (2)
JP (1)	JP4137645B2 (2)
KR (1)	KR20040008175A (2)
CN (1)	CN1509288A (2)
AP (1)	AP1429A (2)
AR (1)	AR035889A1 (2)
AT (1)	ATE303386T1 (2)
BG (1)	BG108344A (2)
CA (1)	CA2446988A1 (2)
CZ (1)	CZ20032917A3 (2)
DE (1)	DE60205888T2 (2)
DO (1)	DOP2002000390A (2)
DZ (1)	DZ3503A1 (2)
EA (1)	EA005529B1 (2)
EE (1)	EE200300557A (2)
ES (1)	ES2245731T3 (2)
GT (1)	GT200200081A (2)
HR (1)	HRP20030911A2 (2)
HU (1)	HUP0304085A3 (2)
IL (1)	IL157874A0 (2)
IS (1)	IS6956A (2)
MA (1)	MA27021A1 (2)
MX (1)	MXPA03010365A (2)
MY (1)	MY134123A (2)
NO (1)	NO20035035D0 (2)
NZ (1)	NZ528209A (2)
OA (1)	OA12600A (2)
PA (1)	PA8545001A1 (2)
PE (1)	PE20021095A1 (2)
PL (1)	PL366774A1 (2)
SK (1)	SK13372003A3 (2)
TN (1)	TNSN03112A1 (2)
UA (1)	UA73421C2 (2)
UY (1)	UY27287A1 (2)
WO (1)	WO2002092597A1 (2)
ZA (1)	ZA200307234B (2)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013163917A1 (zh)	2012-04-13	2013-11-07	连云港金康和信药业有限公司	化合物jk12a及其制备
CN115968283A (zh) *	2020-03-16	2023-04-14	成都科岭源医药技术有限公司	5-ht3受体调节剂、晶型、制备方法和用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69839131T3 (de) *	1997-12-31	2015-05-07	Pfizer Products Inc.	Arylkondensierte azapolycyclische derivate
ATE356625T1 (de) *	2001-11-30	2007-04-15	Pfizer Prod Inc	Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung enthaltend 5,8,14- triazatetracyclo (10.3.1.0(2,11) 0 (4,9) )- hexadeca-2(11) 3, 5,7, 9-pentaene
BRPI0410219A (pt) *	2003-05-20	2006-05-09	Pfizer Prod Inc	composições farmacêuticas de vareniclina
US20050043407A1 (en) *	2003-08-22	2005-02-24	Pfizer Inc	Pharmaceutical composition for the prevention and treatment of addiction in a mammal
BRPI0718600A2 (pt) *	2006-11-09	2013-12-10	Pfizer Prod Inc	Polimorfos de intermediários nicotínicos.
US8440825B2 (en)	2008-03-06	2013-05-14	Medichem S.A.	Fumaric acid salt of varenicline
EP2268639A2 (en)	2008-05-22	2011-01-05	Teva Pharmaceutical Industries Ltd.	Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) *	2008-05-26	2009-12-24	Glenmark	Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) *	2008-07-10	2010-01-14	Revital Lifshitz-Liron	Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
NZ593223A (en) *	2008-12-11	2013-08-30	Cell Therapeutics Inc	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1 (2,6).1(8, 12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
US20100189791A1 (en)	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline malate formulation
CA2801842A1 (en)	2009-06-10	2010-12-16	Actavis Group Ptc Ehf	Amorphous varenicline tartrate co-precipitates
EP2438054A1 (en)	2009-06-22	2012-04-11	Teva Pharmaceutical Industries Ltd.	Solid states forms of varenicline salts and processes for preparation thereof
WO2011140431A1 (en)	2010-05-06	2011-11-10	Teva Pharmaceutical Industries Ltd.	Varenicline salts and crystal forms thereof
WO2018154395A2 (en)	2018-06-11	2018-08-30	Alvogen Malta Operations (Row) Ltd	Controlled release pharmaceutical composition of varenicline
EP3756653A1 (en) *	2019-06-28	2020-12-30	Alfred E. Tiefenbacher (GmbH & Co. KG)	Microparticulate varenicline citrate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69839131T3 (de) *	1997-12-31	2015-05-07	Pfizer Products Inc.	Arylkondensierte azapolycyclische derivate
IL137937A0 (en) *	1999-08-27	2001-10-31	Pfizer Prod Inc	A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal

2002
- 2002-04-26 NZ NZ528209A patent/NZ528209A/en unknown
- 2002-04-26 OA OA1200300290A patent/OA12600A/en unknown
- 2002-04-26 ES ES02724553T patent/ES2245731T3/es not_active Expired - Lifetime
- 2002-04-26 CN CNA028099117A patent/CN1509288A/zh active Pending
- 2002-04-26 IL IL15787402A patent/IL157874A0/xx unknown
- 2002-04-26 DO DO2002000390A patent/DOP2002000390A/es unknown
- 2002-04-26 PL PL02366774A patent/PL366774A1/xx not_active Application Discontinuation
- 2002-04-26 KR KR10-2003-7014752A patent/KR20040008175A/ko not_active Ceased
- 2002-04-26 AT AT02724553T patent/ATE303386T1/de not_active IP Right Cessation
- 2002-04-26 CA CA002446988A patent/CA2446988A1/en not_active Abandoned
- 2002-04-26 HU HU0304085A patent/HUP0304085A3/hu unknown
- 2002-04-26 SK SK1337-2003A patent/SK13372003A3/sk unknown
- 2002-04-26 EA EA200301120A patent/EA005529B1/ru not_active IP Right Cessation
- 2002-04-26 JP JP2002589481A patent/JP4137645B2/ja not_active Expired - Fee Related
- 2002-04-26 DZ DZ023503A patent/DZ3503A1/fr active
- 2002-04-26 DE DE60205888T patent/DE60205888T2/de not_active Expired - Fee Related
- 2002-04-26 CZ CZ20032917A patent/CZ20032917A3/cs unknown
- 2002-04-26 EE EEP200300557A patent/EE200300557A/xx unknown
- 2002-04-26 MX MXPA03010365A patent/MXPA03010365A/es active IP Right Grant
- 2002-04-26 UA UA20031110265A patent/UA73421C2/uk unknown
- 2002-04-26 EP EP02724553A patent/EP1390366B1/en not_active Expired - Lifetime
- 2002-04-26 HR HR20030911A patent/HRP20030911A2/xx not_active Application Discontinuation
- 2002-04-26 WO PCT/IB2002/001450 patent/WO2002092597A1/en not_active Ceased
- 2002-05-06 US US10/139,449 patent/US6787549B2/en not_active Expired - Fee Related
- 2002-05-09 GT GT200200081A patent/GT200200081A/es unknown
- 2002-05-09 AP APAP/P/2002/002522A patent/AP1429A/en active
- 2002-05-10 PE PE2002000392A patent/PE20021095A1/es not_active Application Discontinuation
- 2002-05-13 AR ARP020101735A patent/AR035889A1/es unknown
- 2002-05-13 UY UY27287A patent/UY27287A1/es not_active Application Discontinuation
- 2002-05-13 MY MYPI20021725A patent/MY134123A/en unknown
- 2002-05-14 PA PA20028545001A patent/PA8545001A1/es unknown
2003
- 2003-07-08 TN TNPCT/IB2002/001450A patent/TNSN03112A1/fr unknown
- 2003-09-15 IS IS6956A patent/IS6956A/is unknown
- 2003-09-16 ZA ZA200307234A patent/ZA200307234B/en unknown
- 2003-11-10 MA MA27390A patent/MA27021A1/fr unknown
- 2003-11-11 BG BG108344A patent/BG108344A/bg unknown
- 2003-11-13 NO NO20035035A patent/NO20035035D0/no not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013163917A1 (zh)	2012-04-13	2013-11-07	连云港金康和信药业有限公司	化合物jk12a及其制备
CN115968283A (zh) *	2020-03-16	2023-04-14	成都科岭源医药技术有限公司	5-ht3受体调节剂、晶型、制备方法和用途

Also Published As

Publication number	Publication date
DE60205888D1 (de)	2005-10-06
DZ3503A1 (2)	2002-11-21
KR20040008175A (ko)	2004-01-28
US20030149091A1 (en)	2003-08-07
EP1390366A1 (en)	2004-02-25
TNSN03112A1 (fr)	2005-12-23
IL157874A0 (en)	2004-03-28
DE60205888T2 (de)	2006-07-06
AR035889A1 (es)	2004-07-21
EE200300557A (et)	2004-04-15
MA27021A1 (fr)	2004-12-20
AP2002002522A0 (en)	2002-06-30
UY27287A1 (es)	2003-02-28
UA73421C2 (en)	2005-07-15
OA12600A (en)	2006-06-09
PA8545001A1 (es)	2003-09-05
NZ528209A (en)	2004-09-24
CZ20032917A3 (cs)	2004-07-14
ATE303386T1 (de)	2005-09-15
CA2446988A1 (en)	2002-11-21
GT200200081A (es)	2003-04-22
DOP2002000390A (es)	2003-03-15
PL366774A1 (en)	2005-02-07
US6787549B2 (en)	2004-09-07
EA005529B1 (ru)	2005-04-28
HUP0304085A2 (en)	2004-04-28
ZA200307234B (en)	2004-09-16
MY134123A (en)	2007-11-30
EA200301120A1 (ru)	2004-02-26
HRP20030911A2 (en)	2004-02-29
EP1390366B1 (en)	2005-08-31
HUP0304085A3 (en)	2005-09-28
JP4137645B2 (ja)	2008-08-20
MXPA03010365A (es)	2004-03-16
ES2245731T3 (es)	2006-01-16
AP1429A (en)	2005-06-13
PE20021095A1 (es)	2002-12-14
BG108344A (bg)	2004-12-30
IS6956A (is)	2003-09-15
NO20035035L (no)	2003-11-13
JP2004529186A (ja)	2004-09-24
WO2002092597A1 (en)	2002-11-21
NO20035035D0 (no)	2003-11-13
SK13372003A3 (sk)	2004-08-03

Legal Events

Date	Code	Title	Description
2004-06-30	C06	Publication
2004-06-30	PB01	Publication
2004-09-08	C10	Entry into substantive examination
2004-09-08	SE01	Entry into force of request for substantive examination
2004-11-19	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1062686 Country of ref document: HK
2006-05-17	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2006-05-17	WD01	Invention patent application deemed withdrawn after publication
2010-12-10	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1062686 Country of ref document: HK

Publication	Publication Date	Title
CN1509288A (zh)	2004-06-30	5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐
CN1871003A (zh)	2006-11-29	3－(4－氨基－1－氧代－1,3二氢－异吲哚－2－基)－哌啶－2,6－二酮的多晶型物
CN101031548A (zh)	2007-09-05	N－(4－氟苄基)－n－(1－甲基哌啶－4－基)－n'－(4－(2－甲基丙氧基)－苯基甲基)脲的盐及其制备
CN1243721C (zh)	2006-03-01	取代氨基化合物和它们作为具有镇痛物质的用途
JP2020503298A (ja)	2020-01-30	単環式ｏｇａ阻害剤化合物
CN1287487A (zh)	2001-03-14	氨基苯氧基乙酸衍生物和含有它们的药用组合物
CN1703404A (zh)	2005-11-30	制备10,11－二氢－10－羟基－5H－二苯并(b,f)氮杂䓬－5－甲酰胺的两种对映异构体的对映选择性方法及其新晶形
CN1678614A (zh)	2005-10-05	N－甲基－N(3－{3－[2－噻吩基羰基]－吡唑－[1,5－α]－嘧啶－7－基}苯基)乙酰胺的新型多形体及其相关组合物和方法
CN1437596A (zh)	2003-08-20	苯基哌嗪基衍生物
CN1146562C (zh)	2004-04-21	作为pde4抑制剂的四氢噻喃2,3-二氮杂萘酮类衍生物
CN1798744A (zh)	2006-07-05	作为nmda/nr2b拮抗剂的3－氟－哌啶化合物
CN1756740A (zh)	2006-04-05	具有2,6－二取代苯乙烯基的含氮杂环衍生物
CN1656097A (zh)	2005-08-17	黄嘌呤磷酸二酯酶v抑制剂多晶型物
CN101037437A (zh)	2007-09-19	Flazin类似物及其制备方法与应用
CN1604908A (zh)	2005-04-06	制备棘白菌素衍生物的方法
CN101058543A (zh)	2007-10-24	制备胺衍生物的方法
CN1030611C (zh)	1996-01-03	形式ii地红霉素的制备方法
CN101052393A (zh)	2007-10-10	氮杂双环己烷的新型多晶型物
CN1121403C (zh)	2003-09-17	喹喔啉二酮
CN101039921A (zh)	2007-09-19	3－[5－氯－4－[(2,4－二氟苄基)氧基]－6－氧代嘧啶－1(6h)－基]－n－(2－羟乙基)－4－甲基苯甲酰胺的晶形
CN1869033A (zh)	2006-11-29	R－硫辛酸的氨基丁三醇盐的新的变性体及其制备方法
CN1599730A (zh)	2005-03-23	治疗化合物的柠檬酸盐及其药物组合物
CN1055472C (zh)	2000-08-16	噁唑并喹啉酮衍生物,它们的制备及其在治疗上的应用
CN1158276C (zh)	2004-07-21	具有抑制tnf活性的苯基-和吡啶基-四氢吡啶
HK1062686A (en)	2004-11-19	The citrate salt of 5, 8, 14-triazatetracyclo (10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof

CN1509288A - 5,8,14－三氮杂四环[10.3.1.02，11.04，9]－十六－2(11),3,5,7,9－五烯的柠檬酸盐 - Google Patents

Info

Links

Images

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (1)

Family

ID=23117854

Family Applications (1)

Country Status (37)

Cited By (2)

Families Citing this family (17)

Family Cites Families (2)

Cited By (2)

Also Published As

Similar Documents

Legal Events